Clinical stage biotechnology startup AltruBio, situated in San Francisco, California, has secured up to $225 million in Series B investment.
Investors
- BVF Partners LP
- Blackstone Multi-Asset Investing
- Moon Fund
- RA Capital Management
- Cormorant Asset Management
- Soleus Capital
Use of funds
The business plans to utilize the money to assist existing and upcoming Phase 2 clinical studies in ulcerative colitis (UC) as well as to further the clinical development of its immune checkpoint enhancer (ICE) PSGL-1 agonist antibody, ALTB-268.
About AltruBio
AltruBio is a clinical-stage biotechnology business headed by President and CEO Dr. Judy Chou. The firm’s focus is on creating innovative treatments that use immune checkpoint agonism to improve the efficiency of natural pathways and suppress an overactive immune system. The study team used PSGL-1’s capacity to downregulate chronic effector T-cell activity and promote downregulation after discovering the new role it performs as an immunological checkpoint regulator. Clinical evidence supports the company’s ICE treatment, ALTB-168, by demonstrating how it improves PSGL-1 function.
In a number of conditions, including ulcerative colitis, steroid-refractory acute graft-versus-host disease (SR-aGvHD), psoriatic arthritis, and psoriasis, ALTB-168 is intended to selectively downregulate chronically activated late-stage T-cells. It has been shown to be well tolerated with long-lasting effects. By using the same binding domain and unique mechanism that were shown for ALTB-168, the business is developing ALTB-268, a tetravalent ICE that can be administered subcutaneously and in a manner that is convenient for patients.
AltruBio wants to help patients live better lives by developing long-lasting biologic therapies.